GlassScriptPhysician profile
Keith M Menard
NPI 1487695482
$3,222.85
in general payments reported to CMS, 2019-2025
15 companies · $464 in 2025
The $464 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $15.18 · 2021: $612 · 2022: $344 · 2023: $244 · 2024: $186 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $761.95 | 2019-2025 | Photrexa Viscous and Photrexa, Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $548.26 | 2019-2025 | Total30, Precision 1 |
| Optos, INC. | $389.19 | 2019-2022 | |
| Maculogix, INC. | $342.15 | 2019 | |
| Coopervision INC. | $296.28 | 2019-2022 | |
| Allergan, INC. | $154.19 | 2019 | |
| Sun Pharmaceutical Industries INC. | $135.08 | 2023 | Cequa |
| Bausch & Lomb Americas INC. | $131.48 | 2025 | Xiidra, Miebo, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $118.51 | 2019 | |
| Biotissue Holdings INC. | $113.84 | 2025 | |
| Shire North American Group INC | $89.56 | 2019 | |
| Lkc Technologies, INC. | $77.26 | 2023 | |
| Oyster Point Pharma, INC. | $26.65 | 2022 | |
| Abbvie INC. | $23.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Menard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.